Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company based in La Jolla, California, that engineers multivalent biologic therapies for hard-to-treat cancers. Its lead programs are ozekibart (INBRX-109), a death receptor 5 agonist with a biologics license application under FDA review in conventional chondrosarcoma, and ordastobart (INBRX-106), an OX40 agonist in development for head and neck and lung cancers.
Shares were trading at $76.60 at midday, up $7.54 or 10.92%, from the prior session's close of $69.06. The direction is decisively higher, and the advance extends an intraday move that carried the stock as high as $78.57. Markets are pointing to the company's Ewing sarcoma data presentation at the Connective Tissue Oncology Society 2026 annual meeting as the proximate trigger, layered on top of an oversold technical condition after a steep five-day decline.
Inhibrx disclosed updated Phase 1/2 expansion results for ozekibart combined with irinotecan and temozolomide in relapsed or refractory Ewing sarcoma on November 17. The data were delivered as a poster at CTOS in Seoul on November 19, putting the numbers back in front of the specialist oncology audience during today's U.S. session.
Among 51 response-evaluable patients, the combination produced a 62.7% overall response rate, including two complete responses and 30 partial responses. Another 12 patients achieved stable disease, lifting the disease control rate to 86.3%, and 84.3% of evaluable patients saw measurable tumor shrinkage. Median progression-free survival came in at 6.0 months, versus historical benchmarks of roughly 15% to 30% response rates and 3 to 4 months of progression-free survival for chemotherapy alone. The safety profile showed no evidence of unexpected cumulative hepatotoxicity.
That is a meaningful clinical signal for a company with a market capitalization near $1.13 billion, because it points to a second commercial indication for ozekibart beyond the chondrosarcoma filing already accepted by the FDA. Management said it intends to discuss the Ewing sarcoma results with regulators. The initial market reaction on November 17 and 18 was negative, making today's session a reassessment rather than a first read.
Technical conditions amplified the response. From the November 9 close of $91.74, the stock fell in five straight sessions to $69.06, a decline of 24.7% that pushed the relative strength index to roughly 35 and left shares well beneath both the 50-day and 200-day moving averages near $92.7. With no change to the underlying clinical narrative, that drawdown created room for a sharp counter-trend bid once the data were formally presented.
The supply-demand backdrop is unforgiving. Inhibrx has about 14.77 million shares outstanding but a float of only about 8.08 million, and short interest of roughly 3.39 million shares represents a substantial share of that tradable supply. In a float this small, modest incremental buying can move the tape far more than fundamentals alone would justify, which is consistent with the size of today's move.
Volume was running well ahead of the stock's recent pace, with roughly 163,000 shares traded by late morning against a recent daily average near 226,000, suggesting an elevated full-session tally. The move was company-specific rather than sector-driven, and it diverged from the broad biotech complex, which was not matching a double-digit advance. Technically, the stock is bouncing from deep below its major moving averages while remaining far from the 52-week high of $155.29 — a recovery within a downtrend rather than a breakout.
A score of 0 would mean no meaningful news and an ordinary move; 100 would mean transformative news and a rare, extreme price swing. The score here is 45 out of 100. The verified news is substantial: updated mid-stage data showing a 62.7% response rate and 86.3% disease control in a difficult sarcoma population, material relative to a company of this size, though not a pivotal or regulatory event.
The price move was unusual but not extraordinary. Today's 10.92% advance is roughly 2.9 times the stock's typical daily move of about 3.8% over the past 60 sessions, and only three sessions in that window produced moves of similar or greater magnitude. Strong news and a moderately anomalous move combine into a mid-range score.
The central focus remains the FDA review of ozekibart in conventional chondrosarcoma, alongside commercial launch preparation. Investors will also watch for regulatory feedback on the Ewing sarcoma dataset and for progress in the randomized Phase 2 HexAgon study of ordastobart in HPV-positive head and neck cancer, with initial readouts guided toward mid-2027, as is the Phase 1/2 non-small cell lung cancer study.
Financial durability matters as well: Inhibrx held $199.5 million in cash and equivalents at September 30 and carries $275 million of debt, after a third quarter that produced $2.0 million of revenue from a Pfizer license and a $38.7 million net loss. Analyst consensus remains constructive, with a Buy rating and price targets far above current levels. Risks include clinical setbacks, dilution, thin liquidity, and the possibility that today's rebound fades without sustained volume.
Trending AI Robots is a curated Tickeron section that surfaces the strongest automated trading strategies under present market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but this page highlights only those posting the best performance right now. Bots differ widely by strategy logic, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as conditions change. Reviewing the current leaders can help traders see which approaches are working — explore the page to compare today's top performers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INBX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In 33 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INBX as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 50-day moving average for INBX moved below the 200-day moving average on November 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for INBX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INBX's RSI Oscillator exited the oversold zone, 28 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +14.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in 224 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.481) is normal, around the industry mean (3.596). P/E Ratio (-9.518) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. INBX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in researching and developing biotechnology
Industry Biotechnology